Healthcare Professionals Conference 2017
Rydges on Swanston, 701 Swanston St, Carlton VIC 3053 (map)
Fri 27th Oct 2017, 9:00am to 5:00pm (8 hours)
Hosted by Parkinson’s Victoria, this annual one-day educational conference will offer a unique and specific focus that explores and explains the complexities of managing Parkinson’s in the later stages.
Whilst designed to encourage interaction and peer networking, its primary focus is to equip healthcare professionals with up-to-date tools, research information and confidence to improve quality of life in advanced stages of Parkinson’s.
The program is designed to deliver the following learning outcomes:
- Develop awareness of current evidence based pharmacological and non-pharmacological treatment strategies to support people with advanced Parkinson's
- Increase theoretical knowledge of the impact of non-motor symptoms on functional ability and quality of life
- Understand patterns of neuro-psychiatric and cognitive changes
- Understand the principles of neuro-palliative rehabilitation
- Increase awareness of best practice care to support people experiencing challenging motor and non-motor symptoms
- Develop increased awareness of resources available in the community to assist in the care of people with later stage PD
When: Friday 27 October 2017
Where: Rydges on Swanston, 701 Swanston Street, Carlton
Time: 8:50am registration, tea and coffee on arrival. Conference commences 9:20am, concludes, 4:30pm
Price: Early Bird (book before October 11th) - $120
Regular (on or after October 12th) - $150
0850-0920 Registration, tea and coffee on arrival
0920 Welcome - Ms Emma Collin, CEO, Parkinson's Victoria
0930 Bio Markers of Advanced Disease - Assoc Prof Peter Kempster
1030 Neuropsychiatric Symptoms and Management - Assoc Prof Mark Walterfang
1115 Morning tea
1145 Complex presentations and co-morbidities - Dr Arup Bhattacharya
1245 Managing challenging behaviours - Dr Luke Smith
1415 Neuro-palliative rehabilitation (NPR) model - Dr Jim Howe
1500 Workshop – NPR in movement disorders - Dr Jim Howe, Victor McConvey, Karen Silcock
As a global leader in medical technology, services and solutions, Medtronic improves the health and lives of millions of people each year. We believe our deep clinical, therapeutic and economic expertise can help address the complex challenges — such as rising costs, aging populations, and the burden of chronic disease — faced by families and healthcare systems today. But, we can’t do it alone. That’s why we’re committed to partnering in new ways and developing powerful solutions that deliver better patient outcomes.
Founded in 1949 as a medical repair company, we're now among the world's largest medical technology, services and solutions companies, employing more than 85,000 people worldwide, serving physicians, hospitals and patients in more than 160 countries.
STADA Australia is a speciality pharmaceutical company with a product focus on infusion therapies in Neurology and Pain Management.
We work closely with Britannia Pharmaceuticals in the UK, a wholly owned subsidiary of STADA, to ensure the latest innovations in the management Parkinson’s disease in Europe are brought to patients in Australia and New Zealand.
Pfizer Australia is proud to be part of an industry that has helped treat, cure and eradicate life-threatening diseases. Pfizer seizes opportunities in neuroscience research by mobilizing its industry-leading strengths in small molecules, antibodies, peptides, vaccines, and other biomolecules. Pfizer’s Neuroscience Research Unit is focused on investigating potential cures and therapies for diseases such as Parkinson’s and Alzheimer’s.
Building on its strong global footprint, size and scale, Teva is reaffirming its commitment to place people at the center of our strategy, and enable as many as possible to live better, healthier days.
Teva is committed to increasing access to high-quality healthcare for people across the globe, at every stage of life. We do this by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.